- Home
- EDSA vs CNSP Comparison
EDSA vs CNSP Comparison
Compare EDSA & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- CNSP
- Stock Information
- Founded
- EDSA 2015
- CNSP 2017
- Country
- EDSA Canada
- CNSP United States
- Employees
- EDSA N/A
- CNSP N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- CNSP Health Care
- Exchange
- EDSA Nasdaq
- CNSP Nasdaq
- Market Cap
- EDSA 6.2M
- CNSP 5.6M
- IPO Year
- EDSA N/A
- CNSP 2019
- Fundamental
- Price
- EDSA $2.26
- CNSP $0.82
- Analyst Decision
- EDSA Strong Buy
- CNSP Hold
- Analyst Count
- EDSA 1
- CNSP 1
- Target Price
- EDSA $21.00
- CNSP N/A
- AVG Volume (30 Days)
- EDSA 11.4K
- CNSP 355.0K
- Earning Date
- EDSA 05-09-2025
- CNSP 05-14-2025
- Dividend Yield
- EDSA N/A
- CNSP N/A
- EPS Growth
- EDSA N/A
- CNSP N/A
- EPS
- EDSA N/A
- CNSP N/A
- Revenue
- EDSA N/A
- CNSP N/A
- Revenue This Year
- EDSA N/A
- CNSP N/A
- Revenue Next Year
- EDSA N/A
- CNSP N/A
- P/E Ratio
- EDSA N/A
- CNSP N/A
- Revenue Growth
- EDSA N/A
- CNSP N/A
- 52 Week Low
- EDSA $1.55
- CNSP $0.77
- 52 Week High
- EDSA $5.59
- CNSP $800.00
- Technical
- Relative Strength Index (RSI)
- EDSA 46.91
- CNSP 29.62
- Support Level
- EDSA $2.11
- CNSP $0.99
- Resistance Level
- EDSA $2.34
- CNSP $1.37
- Average True Range (ATR)
- EDSA 0.13
- CNSP 0.16
- MACD
- EDSA -0.01
- CNSP 0.03
- Stochastic Oscillator
- EDSA 40.45
- CNSP 7.04
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.